Phase 1 first-in-human study (85 healthy volunteers, 18 with mild asthma): inhaled londamocitinib was well tolerated; in mild asthma with raised FeNO, 1.4 and 3 mg doses cut mean FeNO by about 50% by day 3 vs no significant reduction with placebo.
RCTn = 103
Jellesmark Jensen et al. First-in-human study for londamocitinib (AZD4604), an inhaled selective JAK1 inhibitor